Vemurafenib Terminated Phase 2 Trials for Melanoma / Metastatic Melanoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01474551Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
NCT01942993The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
NCT01813214The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
NCT01495988Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma